Imp to understand clinical & genomic landscape of specific KRASm in #PancreaticCancer
👇characterisation KRAS G12C (1%)
➡️ similar co-mutations as non-G12C
?⬆️smoking hx & ?⬆️BMI
Congrats Fergus Keane St Vincent's University Hospital (SVUH) HPB Dublin Memorial Sloan Kettering Cancer Center Eileen M O’Reilly
academic.oup.com/jnci/advance-a…

Best part of today was seeing this presented!🌟Glasgow #PancreaticCancer 2024
➡️way too many heterogenous PanINs visualised in 3D! Different KRASm, dominant SBS 1,5 present, why do some progress!❓host factors/TME-great discussions Laura DeLong Wood Fieke Froeling Barbara Grünwald

Thanks for highlighting OncoDaily MDT re-discussion always vital in such cases, albeit rare @matthew86724636 Angela Lamarca Cholangiocarcinoma Foundation AMMF JCO Precision Oncology

Incredible science packed day at Glasgow #PancreaticCancer Symposium 2024 - fighting to understand the evolution & heterogeneity together! Notta Lab Pancreatic Cancer Ireland well done to Fieke Froeling Jen Morton 🏴󠁧󠁢󠁳󠁣󠁴󠁿🇺🇦 Prof David K. Chang Cancer Research UK in Scotland

Christian Magyar from our group presenting on benefits of LEN vs SOR in recurrence post-LT ILTS Arndt Vogel Laia Aceituno ILCA Grainne O'Kane Proud mentor moment

At our Stakeholder meeting last week we were fortunate to hear from returning investigator Michael Kelly Trinity St James's Cancer Institute recently returned from the Peter Mac Cancer Centre in Aus.

Seamus O’Reilly MD PhD Angela Clayton-Lea Beaumont RCSI Cancer Centre Grainne O'Kane Aisling Barry

Watch: youtube.com/watch?v=t1L7Ho…

*We are heading towards precision medicine and want to establish reasonable sequential strategies. In order to do that we need to understand and be able to overcome resistance in development. We need to determine which patients we can target, and then of course we are currently

Super proud of Gonzalo Sapisochin on this huge achievement! More great things to come as the multidisciplinary field of #transplantoncology continues to grow, providing more options for patients ILCA ILTS #HCC #CCA

February 15th is World Cholangiocarcinoma Day. Take action to improve time to diagnosis - be CLEAR:
Clarify, ‍Listen, ‍Explain, ‍Act,‍ Refer #WorldCCADay Trinity St James's Cancer Institute St James's Hospital Trinity College Dublin Grainne O'Kane

The discussions are on 🔥 - transplant vs resection - may not be as clear cut with neoadjuvant and combo therapies- and it’s a packed house! Come join the discussion Vatche G. Agopian Gonzalo Sapisochin Karim J Halazun MD Julie Heimbach Adam Yopp Amit G Singal HCC-LIVE Conference

David James Pinato 🇺🇦 and Marco Sanduzzi Zamparelli discussing immunotherapy and liver transplant for #HCC at the ILCA ILTS consensus conference on liver transplant for #livercancer in Valencia Gonzalo Sapisochin laura kulik Sherrie Bhoori Grainne O'Kane

#EMERALD1 just presented at #GI24 . The first positive phase 3 trial of #TACE plus #systemictherapy #durvalumab #bevacizumab in intermediate #HCC ! ASCO

🔥Efficacy & safety results of FGFR1-3 inhibitor tinengotinib in patients cholangiocarcinoma #GI24
✅ Results from phase II clinical trial
👉FGFR2 naive & pretreated pts
👉Consistent efficacy
👉ORR: 26 - 40%, DCR 90%
🧐Feasible & safe, phs-III ongoing
ESMO - Eur. Oncology @ILCA EASL Education

Lots of 🚨 about the increased incidence of GI cancers in younger patients. What is not highlighted enough is the fact most affected are Women, Asians, Hispanic, and Native Americans!! Hence the importance of reaching out to all for increased awareness and screening. #GI24

Phase 2 ALPACA #PancreaticCancer #GI24
✅Post 3 x GnP induction
✅ Alternating GnP/Gem vs GnP continuous same OS
➡️ Imp. practical study
➡️ I also like biweekly GnP👇 as shown by Tanios Bekaii-Saab, MD Daniel Ahn

ncbi.nlm.nih.gov/pmc/articles/P…

HAIP+systemic chemo in adv liver confined iCCA #GI24
➡️ Phase 2 trial n=50,comparing to historical controls
✅ PR in 46%
✅ 3-yr OS 33%
Impressive data and 👏 Bas Groot Koerkamp
❓molecular profile of those 50!
➡️ Can we enrich for local tx in iCCA?